Hernandez Alexandra 4
4 · Lineage Cell Therapeutics, Inc. · Filed Apr 1, 2021
Insider Transaction Report
Form 4
Hernandez Alexandra
Sr Director Finance/Controller
Transactions
- Exercise/Conversion
Employee Stock Option (Right to Buy)
2021-03-30−6,000→ 39,200 totalExercise: $0.69Exp: 2030-03-17→ Common Shares (6,000 underlying) - Exercise/Conversion
Common Shares, no par value
2021-03-30$0.69/sh+6,000$4,151→ 6,000 total - Award
Employee Stock Option (Right to Buy)
2021-03-15+42,700→ 42,700 totalExercise: $2.43Exp: 2031-03-15→ Common Shares (42,700 underlying) - Sale
Common Shares, no par value
2021-03-30$2.23/sh−6,000$13,380→ 0 total
Footnotes (2)
- [F1]One quarter of the options vest on March 15, 2022 and the balance vest in 36 monthly installments thereafter upon the completion of each month of continuous employment.
- [F2]One quarter of the options vested on March 17, 2021 and the balance vest in 36 monthly installments thereafter upon the completion of each month of continuous employment.